Market revenue in 2023 | USD 1,728.2 million |
Market revenue in 2030 | USD 2,423.8 million |
Growth rate | 5% (CAGR from 2023 to 2030) |
Largest segment | Purity>98% |
Fastest growing segment | Purity>98% |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Purity>98%, Purity<98% |
Key market players worldwide | Merck KGaA, GSK PLC, Cipla Ltd DR, Novartis AG ADR, Sanofi SA, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Mallinckrodt PLC Ordinary Shares - New, Cayman Chemical, Tokyo Chemical Industry, APExBIO Technology, Wilshire Technologies, Biosynth |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crocin market will help companies and investors design strategic landscapes.
Purity>98% was the largest segment with a revenue share of 95.55% in 2023. Horizon Databook has segmented the U.S. crocin market based on purity>98%, purity<98% covering the revenue growth of each sub-segment from 2018 to 2030.
Severe headaches and migraines are an important public health issue in the U.S. Migraines are the most common type of headache in the U.S. According to the Migraine Research Foundation, in 2023, there were more than 39 million people affected by migraines in the U.S. Women are three times more likely get migraines than men.
Moreover, acute and chronic pain affects around 116 million people in the country; the annual economic cost of this condition is between USD 560 and 635 billion. In the U.S., paracetamol is known as acetaminophen. Acetaminophen can treat mild to moderate pain, headaches, and fever.
It is available under Mapap, Panadol, and Tylenol, in addition to generics & store-specific brands. Acetaminophen is available in various OTC formulations, including 500 mg and 325 mg oral tablets & capsules, orally disintegrating tablets or chewables, rapid-release oral liquids, and rectal suppositories.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. crocin market , including forecasts for subscribers. This country databook contains high-level insights into U.S. crocin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account